Techno Venture Management

Helomics Corporation is a personalized healthcare company based in Pittsburgh, Pennsylvania, focused on enhancing cancer care through a range of innovative diagnostic products and services. The company has developed the Precision Cellular Analytical Platform, which analyzes cell cycle and proliferation data over a 25-35 day period. Helomics' offerings include ChemoFx, which assists in selecting effective treatments for gynecologic cancer, and BioSpeciFx, a set of biomarker tests that provide insights into tumor characteristics and potential drug responses. Additionally, Helomics provides GeneFx Colon and GeneFx Lung, microarray-based gene signatures tailored for patients with stage two colon cancer and early-stage non-small cell lung cancer, respectively. The company also engages in tumor profiling services, including bioinformatics and contract research, to support clinical decision-making. Furthermore, Helomics utilizes its D-CHIP digital clinical health insight platform to deliver personalized oncology roadmaps and collaborates with pharmaceutical and diagnostics companies to enhance patient selection for clinical trials. Founded in 1995 and formerly known as Precision Therapeutics, Helomics continues to push the boundaries of precision oncology.

Precision Therapeutics is a pharmaceutical research and development business that develops personalized cancer treatments for patients.

Streaming21 is a solution provider of seamless on-demand and IP broadcasting service platform for connected digital home.

ReVolt Technology is a technology company, which is developing a rechargeable zinc-air battery. ReVolt's batteries may enable more high-power consumer devices, electric vehicles and renewable energy storage. The technology is a result of six years of intense research and development at SINTEF (the largest independent research institute in Scandinavia). Research on material combinations has solved issues historically related to the metal-air technology; power, lifetime and rechargeability.

VPIsystems, originally established as VPI Virtual Photonics in 1997, specializes in developing and marketing network planning software and services tailored for the telecommunications industry, both in the United States and globally. The company's offerings include Photonic Design Automation, which aids in the modeling and optimization of photonic components and subsystems, and OnePlan, an integrated system that facilitates the design and implementation of transitions to IP-based networks for communications service providers, systems integrators, and manufacturers. VPIsystems aims to enhance the efficiency of network planning and engineering processes through predictive network analytics and comprehensive data integration, thereby improving network reliability and supporting informed technology decisions. The company maintains strategic partnerships with prominent firms such as Accenture and HP and is headquartered in Holmdel, New Jersey, with additional offices across Europe, Asia, and Australia. In July 2001, the company rebranded itself as VPIsystems, Inc.

Bluebird bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The company's gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with several organizations, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to advance gene therapies in oncology and immune cell therapies. Additionally, bluebird bio collaborates with various partners to explore T cell receptor product candidates and in vivo genome editing treatments for genetic disorders. Established in 1992 and originally known as Genetix Pharmaceuticals, the company transitioned to its current name in 2010.

iTAC Software AG is a specialized provider of manufacturing execution systems (MES) that serves the global manufacturing industry. Founded in 1998 and headquartered in Montabaur, Germany, with an additional location in Detroit, Michigan, the company offers a range of advanced solutions designed to enhance production efficiency and facilitate Industry 4.0 applications. Its key products include iTAC.ARTES, a middleware layer for enterprise applications; iTAC.MES.Suite, which improves production processes; and iTAC.Trace.Server, aimed at companies seeking to implement autonomous production capabilities. Additionally, iTAC provides various support and consulting services, including educational programs, project preparation, and 24/7 technical assistance. The company's clientele spans multiple sectors, including automotive, electronics, medical technology, and energy. iTAC Software AG operates as a subsidiary of Dürr Aktiengesellschaft.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

Enanta Pharmaceuticals, Inc., established in 1998 and headquartered in Watertown, Massachusetts, is a biotechnology company dedicated to discovering and developing small molecule drugs for treating viral infections and liver diseases. Its primary focus areas include hepatitis C virus (HCV), hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV). Enanta offers glecaprevir, marketed as MAVYRET and MAVIRET, for chronic HCV treatment. Through a collaborative agreement with Abbott Laboratories, the company has developed paritaprevir, an HCV NS3/4A protease inhibitor. Enanta's pipeline also includes direct-acting antiviral inhibitors against HCV and other viral targets.

Infitel International is a provider of solutions for telecommunications value-added services based on intelligent networks (IN platforms).

Pharmasset Inc is a clinical-stage pharmaceutical company focused on the discovery and development of innovative drugs for viral infections. The company specializes in oral therapeutics targeting hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Pharmasset's research centers on nucleoside analogs, compounds that inhibit the enzymes necessary for viral replication. Currently, the company's development pipeline includes three key product candidates: Clevudine, which is aimed at treating HBV and is anticipated to enter Phase 3 clinical trials; R7128, a pro-drug designed for the treatment of HCV, currently in Phase 1 trials; and Racivir, an investigational drug for HIV that is undergoing Phase 2 clinical trials. Through these efforts, Pharmasset aims to provide effective treatment options for patients suffering from these viral infections.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, specializing in the discovery, development, and commercialization of novel orally available small-molecule drugs, particularly allosteric modulators targeting central nervous system (CNS) disorders. The company's leading programs include Dipraglurant, aimed at treating levodopa-induced dyskinesia in Parkinson's disease and dystonia, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB positive allosteric modulator for addiction. Addex Therapeutics emphasizes the advantages of allosteric modulators over traditional non-allosteric molecules, as they may provide improved therapeutic solutions. The company also has a collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for therapeutic use. Founded in 2002, Addex Therapeutics was formerly known as Addex Pharmaceuticals Ltd and rebranded in March 2012.

Cambridge Broadband Networks Limited, established in 1999 and based in Cambridge, United Kingdom, specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers globally. The company’s flagship product, VectaStar, is a multipoint microwave platform that offers mobile backhaul and enterprise access solutions, including VectaStar Gigabit for macro backhaul and VectaStar Metro for multipoint microwave backhaul. Additionally, VectaStar includes a Radio Controller for enhanced network performance. Cambridge Broadband also provides a comprehensive network management system and various applications to assist with equipment configuration and optimization. The company offers extensive consultancy, training, and support services, allowing network operators to effectively design and implement microwave backhaul networks. By delivering high-quality equipment and services, Cambridge Broadband aims to enhance networking capability and efficiency to address the demands of increasing mobile data traffic.

Evotec Neurosciences GmbH is a biotechnology company focused on the discovery and development of small molecule drugs aimed at treating Alzheimer's disease and other neurological disorders. The company utilizes innovative approaches to develop therapeutics that address significant unmet medical needs in the field of neuroscience. By leveraging advanced scientific techniques and expertise, Evotec Neurosciences aims to contribute to the advancement of treatments for complex neurological conditions.

MediGene AG is a biotechnology company focused on immuno-oncology, specializing in the development of differentiated T Cell Receptor engineered T cell (TCR-T) therapies for treating various solid tumor indications with high unmet medical needs. Its primary operating segments are Immunotherapies and Other products, with Immunotherapies comprising T-cell receptor-based adoptive T-cell therapy and DC vaccines. MediGene operates globally, with significant revenue generated from its operations in Germany.

SelectX Pharmaceuticals, Inc. is a Boston-based biopharmaceutical company dedicated to the discovery and development of aminoglycoside therapeutics aimed at addressing unmet medical needs. The company is advancing SXP2523, a next-generation aminoglycoside antibiotic designed to combat drug-resistant gram-negative hospital-acquired infections. Additionally, it is developing an inhaled aminoglycoside antibiotic targeting drug-resistant gram-negative infections in patients with Cystic Fibrosis and other respiratory diseases. Beyond antibiotics, SelectX Pharmaceuticals is also focused on identifying and optimizing non-antibiotic aminoglycoside leads for various therapeutic applications, including cell migration, calcium channels, metalloproteinases, and antiviral strategies. Established in 2002, SelectX Pharmaceuticals was previously known as OmniScience Pharmaceuticals Inc. and has since positioned itself at the forefront of innovative therapeutic development.

Enanta Pharmaceuticals, Inc., established in 1998 and headquartered in Watertown, Massachusetts, is a biotechnology company dedicated to discovering and developing small molecule drugs for treating viral infections and liver diseases. Its primary focus areas include hepatitis C virus (HCV), hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV). Enanta offers glecaprevir, marketed as MAVYRET and MAVIRET, for chronic HCV treatment. Through a collaborative agreement with Abbott Laboratories, the company has developed paritaprevir, an HCV NS3/4A protease inhibitor. Enanta's pipeline also includes direct-acting antiviral inhibitors against HCV and other viral targets.

CoreOptics is a prominent manufacturer of advanced subsystems designed for high-speed optical networking applications in the telecommunications and information technology sectors. The company specializes in 10G and 40G Distortion Tolerant Transponder Modules and integrated circuit solutions, catering to Metro, Regional, and Long Haul optical and data networking markets. CoreOptics advocates for open systems in optical communications networks, enabling efficient data transmission regardless of data rates or fiber types. Their innovative maximum likelihood sequence estimation (MLSE)-based equalization technology is the only field-proven solution available, empowering Tier 1 systems vendors and carriers to enhance their high-performance networks using existing fiber infrastructure. By eliminating the need for Optical Compensators and associated Second Stage Amplifiers, CoreOptics' products can significantly reduce initial deployment costs for customers, making them a valuable partner in the evolution of optical networking.

Helomics Corporation is a personalized healthcare company based in Pittsburgh, Pennsylvania, focused on enhancing cancer care through a range of innovative diagnostic products and services. The company has developed the Precision Cellular Analytical Platform, which analyzes cell cycle and proliferation data over a 25-35 day period. Helomics' offerings include ChemoFx, which assists in selecting effective treatments for gynecologic cancer, and BioSpeciFx, a set of biomarker tests that provide insights into tumor characteristics and potential drug responses. Additionally, Helomics provides GeneFx Colon and GeneFx Lung, microarray-based gene signatures tailored for patients with stage two colon cancer and early-stage non-small cell lung cancer, respectively. The company also engages in tumor profiling services, including bioinformatics and contract research, to support clinical decision-making. Furthermore, Helomics utilizes its D-CHIP digital clinical health insight platform to deliver personalized oncology roadmaps and collaborates with pharmaceutical and diagnostics companies to enhance patient selection for clinical trials. Founded in 1995 and formerly known as Precision Therapeutics, Helomics continues to push the boundaries of precision oncology.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annual funding of £3.8 million.

Intercell AG, a biotechnology company, engages in the design and development of vaccines for the prevention and treatment of infectious diseases. It discovers and develops antigens and adjuvants, which are derived from its proprietary technology platforms. The company was founded in 1998 and is headquartered in Vienna, Austria.

Nanostream Inc. provides products and services for pharmaceutical and biotech companies.

Acorda Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders. Founded in 1995 and headquartered in Ardsley, New York, the company markets Ampyra (dalfampridine), an oral drug approved by the FDA to improve walking in patients with multiple sclerosis (MS). In Europe, this drug is marketed as Fampyra. Acorda also markets Selincro for alcohol dependence in Europe and Zanaflex Capsules for spasticity management. Additionally, the company develops Inbrija for treating OFF periods in Parkinson’s disease and ARCUS for acute migraine. Other pipeline products include rHIgM22 for MS and Cimaglermin alfa for heart failure. Acorda has collaborations with Biogen Inc. for Ampyra's development and commercialization.

Sirna Therapeutics is a biotechnology company focused on developing therapies based on RNA interference (RNAi), a groundbreaking scientific discovery with the potential to transform disease treatment. By harnessing the capabilities of RNAi, Sirna Therapeutics aims to create innovative solutions that address various illnesses, positioning itself at the forefront of this emerging field. The company's commitment to advancing RNAi-based therapies highlights its role in the evolving landscape of medical treatment, with the goal of improving patient outcomes through targeted interventions.

ClearCube Technology is a pioneer in the centralized computing industry, known for creating the first blade PC and continuing to lead in centralized and virtualized computing innovations. The company offers a comprehensive range of specialized PCoIP desktop zero clients and blade PCs designed for diverse user needs, from task-oriented employees to power users in engineering fields. ClearCube's products include highly secure zero clients with integrated token readers and various connectivity options, all optimized for seamless integration with VMware Horizon virtualization products. The company's solutions are widely adopted across thousands of federal and commercial locations, including prominent financial services firms, healthcare organizations, and government agencies such as the Department of Defense and Homeland Security. ClearCube focuses on providing secure, efficient, and manageable computing resources that address the cost savings and security requirements of centralization and virtualization initiatives, thereby enhancing the information technology infrastructure of its clients.

Idenix Pharmaceuticals is a biopharmaceutical company focused on discovering and developing drugs for the treatment of viral diseases, primarily targeting hepatitis C virus (HCV). With operations in the United States and Europe, the company's research efforts have led to significant advancements in HCV treatment, including the completion of a proof-of-concept clinical trial in treatment-naive HCV genotype I infected patients. Idenix has also initiated a phase IIa clinical trial to evaluate its lead drug candidate, IDX184, in combination with existing therapies. In addition to HCV, Idenix is developing products and candidates aimed at treating hepatitis B virus (HBV), human immunodeficiency virus type I (HIV), and acquired immune deficiency syndrome (AIDS).

Direvo Industrial Biotechnology GmbH is a privately owned company based in Cologne, Germany, specializing in the development and marketing of biology-based products and processes for non-pharmaceutical applications. Founded in 2008, the company utilizes its expertise in enzymes, microbes, and process optimization to create bio-based solutions across various sectors, including clean energy, clean chemistry, and biomass conversion. Direvo offers a range of innovative platforms, such as the BluZy portfolio, designed for the grain ethanol industry, which includes products that enhance the nutritional value of bio-ethanol by-products and improve process efficiency in ethanol production. Additionally, the company provides the BluServ platform, focused on automated high-throughput screening for protein and strain engineering, and the BluCon technology platform, which converts non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with global leaders in the industry to deliver customized solutions tailored to specific market needs.

Cardion is a biopharmaceutical company that integrates synergistic local gene delivery, stem cell engineering, and tolerance induction capabilities to build cardiovascular gene therapy products. Cardion was founded in 1996 and is based in Erkrath, Nordrhein-Westfalen.

CoreOptics is a prominent manufacturer of advanced subsystems designed for high-speed optical networking applications in the telecommunications and information technology sectors. The company specializes in 10G and 40G Distortion Tolerant Transponder Modules and integrated circuit solutions, catering to Metro, Regional, and Long Haul optical and data networking markets. CoreOptics advocates for open systems in optical communications networks, enabling efficient data transmission regardless of data rates or fiber types. Their innovative maximum likelihood sequence estimation (MLSE)-based equalization technology is the only field-proven solution available, empowering Tier 1 systems vendors and carriers to enhance their high-performance networks using existing fiber infrastructure. By eliminating the need for Optical Compensators and associated Second Stage Amplifiers, CoreOptics' products can significantly reduce initial deployment costs for customers, making them a valuable partner in the evolution of optical networking.

Neuro3d is a biopharmaceutical start-up that aims at virtual treatment and drug development for mental and behavioral disorders.

Enanta Pharmaceuticals, Inc., established in 1998 and headquartered in Watertown, Massachusetts, is a biotechnology company dedicated to discovering and developing small molecule drugs for treating viral infections and liver diseases. Its primary focus areas include hepatitis C virus (HCV), hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV). Enanta offers glecaprevir, marketed as MAVYRET and MAVIRET, for chronic HCV treatment. Through a collaborative agreement with Abbott Laboratories, the company has developed paritaprevir, an HCV NS3/4A protease inhibitor. Enanta's pipeline also includes direct-acting antiviral inhibitors against HCV and other viral targets.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, specializing in the discovery, development, and commercialization of novel orally available small-molecule drugs, particularly allosteric modulators targeting central nervous system (CNS) disorders. The company's leading programs include Dipraglurant, aimed at treating levodopa-induced dyskinesia in Parkinson's disease and dystonia, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB positive allosteric modulator for addiction. Addex Therapeutics emphasizes the advantages of allosteric modulators over traditional non-allosteric molecules, as they may provide improved therapeutic solutions. The company also has a collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for therapeutic use. Founded in 2002, Addex Therapeutics was formerly known as Addex Pharmaceuticals Ltd and rebranded in March 2012.

Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Alfabet is a company that specializes in change management software, focusing on enterprise information technology architecture planning. Founded in 1997 and based in Berlin, with U.S. headquarters in Cambridge, Massachusetts, Alfabet enables organizations to strategically plan and manage their IT to align with business objectives. Its planningIT software distinguishes itself by tightly integrating business priorities with IT deliverables and ongoing initiatives. This holistic and collaborative approach ensures continuous transparency regarding the evolution of IT and business information, processes, and roles. Alfabet serves a diverse global user community of 40,000 IT professionals across more than 40 countries, spanning various industries such as automotive, financial services, telecommunications, logistics, and high-tech. Notable clients include international corporations like Credit Suisse, Munich Re, BMW, and Deutsche Bahn, among others.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

ParadigmGenetics is a biotechnology company at the forefront of life science and gene discovery, focused on metabolic disorders. Leveraging cutting-edge technology and research methodologies, ParadigmGenetics strives to develop innovative solutions that contribute to the diagnosis, treatment, and prevention of metabolic disorders, aiming to make significant strides in the fields of biotechnology and human health.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

SelectX Pharmaceuticals, Inc. is a Boston-based biopharmaceutical company dedicated to the discovery and development of aminoglycoside therapeutics aimed at addressing unmet medical needs. The company is advancing SXP2523, a next-generation aminoglycoside antibiotic designed to combat drug-resistant gram-negative hospital-acquired infections. Additionally, it is developing an inhaled aminoglycoside antibiotic targeting drug-resistant gram-negative infections in patients with Cystic Fibrosis and other respiratory diseases. Beyond antibiotics, SelectX Pharmaceuticals is also focused on identifying and optimizing non-antibiotic aminoglycoside leads for various therapeutic applications, including cell migration, calcium channels, metalloproteinases, and antiviral strategies. Established in 2002, SelectX Pharmaceuticals was previously known as OmniScience Pharmaceuticals Inc. and has since positioned itself at the forefront of innovative therapeutic development.

Altor BioScience Corporation is a biopharmaceutical company based in Miramar, Florida, specializing in the discovery, development, and commercialization of immunotherapeutic agents aimed at treating cancer, viral infections, and autoimmune diseases. Founded in 2002, the company focuses on the immunostimulatory properties of cytokines such as IL-15 and IL-2, which enhance the activation and proliferation of immune cells critical for combating malignancies and infections. Altor's product portfolio includes several candidates in various stages of development, such as ALT-801, a T-cell receptor-targeted therapy for cancer, and ALT-803, an IL-15 superagonist for solid tumors. Additionally, the company offers STAR Fusion and STAR Multimer Reagents for diagnosing and targeting cancer and viral infections, as well as tools for the detection of disease targets on cell surfaces. Altor BioScience aims to leverage its innovative technologies to advance treatment options for patients with challenging health conditions.

Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

IC Mechanics is a manufacturer specializing in electronic chips and semiconductors, particularly in the design of micro-electromechanical systems (MEMS) sensors. The company aims to revolutionize the design, manufacturing, and application of smart MEMS sensor integrated circuits (ICs) by offering products that are cost-effective, more sensitive, and capable of higher bandwidth, all while being smaller and lighter than existing alternatives. This innovation is achieved through a unique sensor geometry and a manufacturing process that utilizes commodity CMOS VLSI wafers. By enhancing the standards for cost, performance, and size, IC Mechanics is positioned to facilitate the development of new devices and applications across various markets, catering specifically to original equipment manufacturers (OEMs) seeking low-cost, highly integrated motion sensing and control solutions.

Cambridge Broadband Networks Limited, established in 1999 and based in Cambridge, United Kingdom, specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers globally. The company’s flagship product, VectaStar, is a multipoint microwave platform that offers mobile backhaul and enterprise access solutions, including VectaStar Gigabit for macro backhaul and VectaStar Metro for multipoint microwave backhaul. Additionally, VectaStar includes a Radio Controller for enhanced network performance. Cambridge Broadband also provides a comprehensive network management system and various applications to assist with equipment configuration and optimization. The company offers extensive consultancy, training, and support services, allowing network operators to effectively design and implement microwave backhaul networks. By delivering high-quality equipment and services, Cambridge Broadband aims to enhance networking capability and efficiency to address the demands of increasing mobile data traffic.

Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.

Nanostream Inc. provides products and services for pharmaceutical and biotech companies.

B-there.com provides online event management solutions for the meeting, trade show, and convention industries. It is based in Westport, Connecticut.

Curacyte GmbH is a biopharmaceutical company based in Munich, Germany, founded in 2001. It specializes in developing innovative therapeutics for acute and critical care, focusing on areas such as hematology, antithrombosis, and oncology. The company's research efforts aim to create advanced biopharmaceutics that address urgent medical needs, providing new treatment options for patients with critical diseases.

Pharmasset Inc is a clinical-stage pharmaceutical company focused on the discovery and development of innovative drugs for viral infections. The company specializes in oral therapeutics targeting hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Pharmasset's research centers on nucleoside analogs, compounds that inhibit the enzymes necessary for viral replication. Currently, the company's development pipeline includes three key product candidates: Clevudine, which is aimed at treating HBV and is anticipated to enter Phase 3 clinical trials; R7128, a pro-drug designed for the treatment of HCV, currently in Phase 1 trials; and Racivir, an investigational drug for HIV that is undergoing Phase 2 clinical trials. Through these efforts, Pharmasset aims to provide effective treatment options for patients suffering from these viral infections.

Iolon, Inc. is a privately held company specializing in optical networking components, focusing on high-performance tunable devices for advanced fiber optic networks. The company's initial product is a high-powered external cavity tunable laser source, designed for high bit rate and long-haul applications. Iolon also plans to expand its product offerings to include tunable filters, optical switches, polarization controllers, spectral monitors, and universal transponders. The company leverages its platform technology, which incorporates patented micro-optics, MEMS, and advanced servo control technologies, to facilitate advanced automation for high-volume manufacturing. Iolon's products are critical for transmitting, monitoring, and receiving optical signals within optical networks and for test and measurement equipment.

Zeptosens is an ultra-sensitive microarray platform for quantitative proteomic investigations. It provides microarray platforms for sensitive and quantitative protein profiling, and signaling pathway analysis by reverse protein arrays. Its products include ZeptoREADER, a microarray reader for Zeptosens planar wave guide technology; ZeptoMARK protein microarray chips and ZeptoCARRIER for various data points, which are split into arrays. The company also offers proteinarray services, including protein profiling for various samples, such as cell lines, tissues, microdissected cells, and depleted serums; and assay development. In addition, it provides training services, technical and applications support, and technical service and maintenance. The company’s products are used in various applications, including biomarker/target discovery and validation, cell-based screening, mode of action profiling, selectivity profiling, and toxicology investigation. Its customers include pharma research and development companies, biotech companies, and academic institutions. Zeptosens was founded in 2002 and is headquartered in Wilderswil, Switzerland.

Talia is a top-tier provider of Internet, voice, and video services, recognised as a market leader throughout the Middle East, Africa, and Europe. Experts in satellite, voice, video, and broadcast communications, Talia provide global network coverage, enabling enterprises, PTTs, mobile carriers, and broadcasters to connect to the largest global meet me room, and linking the major regional telecoms hubs around the world.

EpiCept Corporation, headquartered in Englewood Cliffs, New Jersey, with a subsidiary in Munich, Germany, specializes in the development of innovative pharmaceutical products aimed at treating pain and cancer. The company focuses on creating safe and effective prescription pain management solutions that utilize a topical delivery system, distinguishing itself from traditional systemic or transdermal methods. EpiCept is committed to exploring partnerships for co-marketing, co-promotion, licensing, and distribution with third-party collaborators to expand its reach in the market. The company's products are supported by a robust patent portfolio, reflecting its dedication to protecting its innovations and capitalizing on the significant market potential of its offerings.

Talia specializes in research, development, design, and production of eyecare diagnostic medical devices for the ophthalmology industry.

Precision Therapeutics is a pharmaceutical research and development business that develops personalized cancer treatments for patients.

CoreOptics is a prominent manufacturer of advanced subsystems designed for high-speed optical networking applications in the telecommunications and information technology sectors. The company specializes in 10G and 40G Distortion Tolerant Transponder Modules and integrated circuit solutions, catering to Metro, Regional, and Long Haul optical and data networking markets. CoreOptics advocates for open systems in optical communications networks, enabling efficient data transmission regardless of data rates or fiber types. Their innovative maximum likelihood sequence estimation (MLSE)-based equalization technology is the only field-proven solution available, empowering Tier 1 systems vendors and carriers to enhance their high-performance networks using existing fiber infrastructure. By eliminating the need for Optical Compensators and associated Second Stage Amplifiers, CoreOptics' products can significantly reduce initial deployment costs for customers, making them a valuable partner in the evolution of optical networking.

ClearCube Technology is a pioneer in the centralized computing industry, known for creating the first blade PC and continuing to lead in centralized and virtualized computing innovations. The company offers a comprehensive range of specialized PCoIP desktop zero clients and blade PCs designed for diverse user needs, from task-oriented employees to power users in engineering fields. ClearCube's products include highly secure zero clients with integrated token readers and various connectivity options, all optimized for seamless integration with VMware Horizon virtualization products. The company's solutions are widely adopted across thousands of federal and commercial locations, including prominent financial services firms, healthcare organizations, and government agencies such as the Department of Defense and Homeland Security. ClearCube focuses on providing secure, efficient, and manageable computing resources that address the cost savings and security requirements of centralization and virtualization initiatives, thereby enhancing the information technology infrastructure of its clients.

Axxom is a software development business that specializes in distribution, logistics, and production automation business solutions.

Direvo Industrial Biotechnology GmbH is a privately owned company based in Cologne, Germany, specializing in the development and marketing of biology-based products and processes for non-pharmaceutical applications. Founded in 2008, the company utilizes its expertise in enzymes, microbes, and process optimization to create bio-based solutions across various sectors, including clean energy, clean chemistry, and biomass conversion. Direvo offers a range of innovative platforms, such as the BluZy portfolio, designed for the grain ethanol industry, which includes products that enhance the nutritional value of bio-ethanol by-products and improve process efficiency in ethanol production. Additionally, the company provides the BluServ platform, focused on automated high-throughput screening for protein and strain engineering, and the BluCon technology platform, which converts non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with global leaders in the industry to deliver customized solutions tailored to specific market needs.

Vividence offers e-businesses with market information services and evaluation applications. It provides consulting services that focus on online customer experience, market trends, and industry strategies. Vividence enables individuals to earn gift cards by evaluating and giving feedback on e-commerce sites. Vividence was founded in 1998 and is based in San Mateo, California.

NanoGram Corporation is a nanotechnology company that develops and manufactures products for advanced applications in photovoltaics, electronics, and displays. It offers a customized application-specific nanotechnology platform that provides tailored nanoscale compositions for various industries, including optical, electronic, imaging, biomedical, and energy sectors. The company has successfully incubated and spun out two notable entities, NeoPhotonics and NanoGram Devices. With offices in Tokyo and Seoul, NanoGram enhances its presence in Asia through strategic partnerships, including a collaboration with Nagase & Co., Ltd/Nagase ChemteX Corporation, facilitating development and manufacturing supply relationships in Japan and addressing expanding market opportunities in Korea.

Enanta Pharmaceuticals, Inc., established in 1998 and headquartered in Watertown, Massachusetts, is a biotechnology company dedicated to discovering and developing small molecule drugs for treating viral infections and liver diseases. Its primary focus areas include hepatitis C virus (HCV), hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV). Enanta offers glecaprevir, marketed as MAVYRET and MAVIRET, for chronic HCV treatment. Through a collaborative agreement with Abbott Laboratories, the company has developed paritaprevir, an HCV NS3/4A protease inhibitor. Enanta's pipeline also includes direct-acting antiviral inhibitors against HCV and other viral targets.

Impress Software Solutions, Inc. specializes in developing packaged integration applications that facilitate the integration of project management and geographical information systems with SAP. Its notable products include Impress for EPM, which enables synchronization of project-related data between SAP PM/PS and Microsoft Project or Primavera, and Impress for GIS, which links SAP assets with GIS features to maintain consistent asset information across systems. The company addresses critical needs in plant turnarounds, routine maintenance, information technology, capital projects, and spatial asset management. Serving a diverse range of industries including energy and utilities, oil and gas, aerospace and defense, chemicals, and engineering and construction, Impress Software has established strategic partnerships with recognized entities such as Accenture, ESRI, Microsoft, Primavera, and SAP. Founded in 1997 and headquartered in Waltham, Massachusetts, the company also has offices in Hannover, Germany, and Huizerstraatweg, the Netherlands, and operates as a subsidiary of Impress Software GmbH.

Streaming21 is a solution provider of seamless on-demand and IP broadcasting service platform for connected digital home.

Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.

Cambridge Broadband Networks Limited, established in 1999 and based in Cambridge, United Kingdom, specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers globally. The company’s flagship product, VectaStar, is a multipoint microwave platform that offers mobile backhaul and enterprise access solutions, including VectaStar Gigabit for macro backhaul and VectaStar Metro for multipoint microwave backhaul. Additionally, VectaStar includes a Radio Controller for enhanced network performance. Cambridge Broadband also provides a comprehensive network management system and various applications to assist with equipment configuration and optimization. The company offers extensive consultancy, training, and support services, allowing network operators to effectively design and implement microwave backhaul networks. By delivering high-quality equipment and services, Cambridge Broadband aims to enhance networking capability and efficiency to address the demands of increasing mobile data traffic.

TANTAU Software Inc. is a leading provider of software and services that enable enterprises to conduct high-volume, secure, mobile ecommerce transactions while maintaining direct access to their customer. TANTAU's blue-chip customer base includes major financial institutions and stock exchanges around the world. Strategic alliances include Nokia, Hewlett-Packard, Compaq, NEON Systems and Baltimore Technologies. TANTAU is a member of the WAP Forum and Radicchio, the global industry consortium that promotes security for wireless ecommerce. Headquartered in Austin, Texas, TANTAU is a global company with development and sales offices around the world, including Australia, Finland, Germany, Switzerland, the United Kingdom and the United States.

HepaVec AG is a privately held biotechnology company, focused on the development of novel therapeutic products for addressing malignant and genetic liver diseases, and on cell engineering of hepatocytes (liver cells). HepaVec has developed new gene transfer systems (vectors), derivatives of baculovirus and an ovine (sheep) adenovirus (OAV), which enable efficient and specific delivery of therapeutic genes into human liver cells. In the combat against liver cancer, HepaVec's lead product regulates the cell cycle to selectively drive cancer cells to programmed cell death (apoptosis) and is scheduled to enter a Phase I/II clinical trial in 2000.

PolyTrax Information Technology AG is a logistics and supply chain company located in Germany. The company specializes in developing power line communications technology that enables communication within buildings by utilizing existing power cables as the network infrastructure. This innovative approach aims to enhance connectivity and streamline communications in various environments, leveraging the existing electrical setup to provide efficient networking solutions.

Gold Wire Technology is a U.S.-based software company founded in 1997 that specializes in network configuration management tools for large data communication distributors. The company develops, sells, and supports infrastructure integrity assurance solutions tailored for enterprises operating in sectors where revenue or compliance is critical, including financial services, retail, automotive, healthcare, and pharmaceuticals. Gold Wire Technology focuses on providing software designed to control and manage the configuration of services for internet service providers, ensuring the reliability and integrity of their network operations. The company was acquired by Intelliden in 2004.

EpiCept Corporation, headquartered in Englewood Cliffs, New Jersey, with a subsidiary in Munich, Germany, specializes in the development of innovative pharmaceutical products aimed at treating pain and cancer. The company focuses on creating safe and effective prescription pain management solutions that utilize a topical delivery system, distinguishing itself from traditional systemic or transdermal methods. EpiCept is committed to exploring partnerships for co-marketing, co-promotion, licensing, and distribution with third-party collaborators to expand its reach in the market. The company's products are supported by a robust patent portfolio, reflecting its dedication to protecting its innovations and capitalizing on the significant market potential of its offerings.

Zeptosens is an ultra-sensitive microarray platform for quantitative proteomic investigations. It provides microarray platforms for sensitive and quantitative protein profiling, and signaling pathway analysis by reverse protein arrays. Its products include ZeptoREADER, a microarray reader for Zeptosens planar wave guide technology; ZeptoMARK protein microarray chips and ZeptoCARRIER for various data points, which are split into arrays. The company also offers proteinarray services, including protein profiling for various samples, such as cell lines, tissues, microdissected cells, and depleted serums; and assay development. In addition, it provides training services, technical and applications support, and technical service and maintenance. The company’s products are used in various applications, including biomarker/target discovery and validation, cell-based screening, mode of action profiling, selectivity profiling, and toxicology investigation. Its customers include pharma research and development companies, biotech companies, and academic institutions. Zeptosens was founded in 2002 and is headquartered in Wilderswil, Switzerland.

Neolinear is a developer of software focused on analog and mixed-signal silicon design. The company specializes in creating mixed-signal chips that integrate both analog and digital circuitry, catering primarily to the consumer and communications markets. Neolinear's advanced analog design technology plays a vital role in enhancing the performance and differentiation of semiconductors, which are increasingly reliant on sophisticated analog components.

A development stage biotechnology company with products for cardiovascular, cancer and inflammatory diseases.

Definiens is a provider of image analysis and data mining solutions specifically designed for quantitative digital pathology within the life sciences, diagnostic biomarkers, and healthcare sectors. The company's software delivers detailed insights from whole tissue slides, cell-based assays, and full body scans, enabling the integration of this information with data from various sources. By automating analysis workflows, Definiens enhances the capabilities of pharmaceutical and biotechnology companies, research institutions, clinical service organizations, and pathologists, facilitating informed decision-making in research, diagnostics, and therapy. Headquartered in Munich, Germany, with additional offices in the United States, Definiens aims to advance research, contribute to the development of personalized medicine, and improve patient outcomes.

Curacyte GmbH is a biopharmaceutical company based in Munich, Germany, founded in 2001. It specializes in developing innovative therapeutics for acute and critical care, focusing on areas such as hematology, antithrombosis, and oncology. The company's research efforts aim to create advanced biopharmaceutics that address urgent medical needs, providing new treatment options for patients with critical diseases.

WILEX a biopharmaceutical company, develops drugs and diagnostic agents to detect cancer, treat malignant tumours, and prevent metastases. Its product line includes RENCAREX, a phase III substance for the treatment of non-metastatic renal cell cancer; REDECTANE, a phase III substance for the treatment of renal mass; and MESUPRON, a phase II substance for the treatment of pancreatic and breast cancer. The company's products also comprise the MEK inhibitor WX-554, which is under Phase I clinical trial; and the other oncology projects, including PI3K inhibitor WX-037 and three antibody programmes under preclinical development. It has a strategic alliance with UCB Pharma S.A. to develop preclinical oncology portfolio. The company was founded in 1997 and is headquartered in Munich, Germany.

Ark Therapeutics is a biotechnology company that develops products and therapies for vascular diseases and cancer.

Transave is a biotechnology research company that develops medicines and treatments for lung diseases.

TravelTainment develops software solutions for the travel distribution on the Internet and at travel agencies.

CyDex specializes in drug delivery solutions like licensing and commercializing cyclodextrins for pharmaceutical and biotechnology uses.

Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

TANTAU Software Inc. is a leading provider of software and services that enable enterprises to conduct high-volume, secure, mobile ecommerce transactions while maintaining direct access to their customer. TANTAU's blue-chip customer base includes major financial institutions and stock exchanges around the world. Strategic alliances include Nokia, Hewlett-Packard, Compaq, NEON Systems and Baltimore Technologies. TANTAU is a member of the WAP Forum and Radicchio, the global industry consortium that promotes security for wireless ecommerce. Headquartered in Austin, Texas, TANTAU is a global company with development and sales offices around the world, including Australia, Finland, Germany, Switzerland, the United Kingdom and the United States.

Infitel International is a provider of solutions for telecommunications value-added services based on intelligent networks (IN platforms).

Enanta Pharmaceuticals, Inc., established in 1998 and headquartered in Watertown, Massachusetts, is a biotechnology company dedicated to discovering and developing small molecule drugs for treating viral infections and liver diseases. Its primary focus areas include hepatitis C virus (HCV), hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV). Enanta offers glecaprevir, marketed as MAVYRET and MAVIRET, for chronic HCV treatment. Through a collaborative agreement with Abbott Laboratories, the company has developed paritaprevir, an HCV NS3/4A protease inhibitor. Enanta's pipeline also includes direct-acting antiviral inhibitors against HCV and other viral targets.

Ingenium Pharmaceuticals AG is discovers and develops molecules for the treatment of neuronal and autoimmune diseases.

Breonics is a biomedical research and development company focused on advancing organ and tissue transplantation. Its flagship innovation, Exsanguinous Metabolic Support (EMS) technology, significantly expands the criteria for kidney donors by including patients who would typically be ineligible. This groundbreaking technology maintains the oxidative metabolism and functionality of organs and tissues while they are isolated from the body, thereby extending the recovery time for organs. By addressing the technical challenges associated with organ donation, Breonics aims to more than double the number of transplantable kidneys available worldwide, ultimately enhancing the capabilities of healthcare practitioners in the field of organ transplants.

Intercell AG, a biotechnology company, engages in the design and development of vaccines for the prevention and treatment of infectious diseases. It discovers and develops antigens and adjuvants, which are derived from its proprietary technology platforms. The company was founded in 1998 and is headquartered in Vienna, Austria.

Axxima Pharmaceuticals is a drug discovery and development company focused on creating innovative antibiotic and antiviral therapies. The company specializes in developing small molecule compounds that inhibit signal transduction pathways essential for the survival of various pathogens. By leading research in pathogen-host signal transduction, Axxima aims to address critical challenges in infectious disease treatment and contribute to the advancement of medical science.

Impress Software Solutions, Inc. specializes in developing packaged integration applications that facilitate the integration of project management and geographical information systems with SAP. Its notable products include Impress for EPM, which enables synchronization of project-related data between SAP PM/PS and Microsoft Project or Primavera, and Impress for GIS, which links SAP assets with GIS features to maintain consistent asset information across systems. The company addresses critical needs in plant turnarounds, routine maintenance, information technology, capital projects, and spatial asset management. Serving a diverse range of industries including energy and utilities, oil and gas, aerospace and defense, chemicals, and engineering and construction, Impress Software has established strategic partnerships with recognized entities such as Accenture, ESRI, Microsoft, Primavera, and SAP. Founded in 1997 and headquartered in Waltham, Massachusetts, the company also has offices in Hannover, Germany, and Huizerstraatweg, the Netherlands, and operates as a subsidiary of Impress Software GmbH.

Morphochem is a biotechnology company focused on research and development in the pharmaceutical sector. The company is innovating an intravenous therapy for Clostridium difficile infection (CDI), utilizing a novel antibacterial compound known as MCB3681. By concentrating on the high-speed parallel synthesis of new chemical entities, Morphochem aims to discover and develop drug candidates that address unmet medical needs in various therapeutic areas. The company's efforts are directed towards making significant advancements in treatment options for patients suffering from CDI.

EpiCept Corporation, headquartered in Englewood Cliffs, New Jersey, with a subsidiary in Munich, Germany, specializes in the development of innovative pharmaceutical products aimed at treating pain and cancer. The company focuses on creating safe and effective prescription pain management solutions that utilize a topical delivery system, distinguishing itself from traditional systemic or transdermal methods. EpiCept is committed to exploring partnerships for co-marketing, co-promotion, licensing, and distribution with third-party collaborators to expand its reach in the market. The company's products are supported by a robust patent portfolio, reflecting its dedication to protecting its innovations and capitalizing on the significant market potential of its offerings.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

VPIsystems, originally established as VPI Virtual Photonics in 1997, specializes in developing and marketing network planning software and services tailored for the telecommunications industry, both in the United States and globally. The company's offerings include Photonic Design Automation, which aids in the modeling and optimization of photonic components and subsystems, and OnePlan, an integrated system that facilitates the design and implementation of transitions to IP-based networks for communications service providers, systems integrators, and manufacturers. VPIsystems aims to enhance the efficiency of network planning and engineering processes through predictive network analytics and comprehensive data integration, thereby improving network reliability and supporting informed technology decisions. The company maintains strategic partnerships with prominent firms such as Accenture and HP and is headquartered in Holmdel, New Jersey, with additional offices across Europe, Asia, and Australia. In July 2001, the company rebranded itself as VPIsystems, Inc.

Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.

MediGene AG is a biotechnology company focused on immuno-oncology, specializing in the development of differentiated T Cell Receptor engineered T cell (TCR-T) therapies for treating various solid tumor indications with high unmet medical needs. Its primary operating segments are Immunotherapies and Other products, with Immunotherapies comprising T-cell receptor-based adoptive T-cell therapy and DC vaccines. MediGene operates globally, with significant revenue generated from its operations in Germany.